Antioxidant Inflammation Modulators for Obesity Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current anti-obesity treatments are limited by significant side effects and lack of efficacy, particularly when used in combination with other medications, and there is a need for safe and effective weight loss solutions for obese patients.

Innovation Solution

Administration of selective activators of the antioxidant transcription factor Nrf2, such as antioxidant inflammation modulators (AIMs), which reduce weight by activating Nrf2 and inhibiting NF-κB, with compounds like bardoxolone methyl being effective in inducing weight loss and improving kidney function, glycemic control, and insulin resistance.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional anti-obesity drugs are used, then weight loss efficacy is achieved, but significant side effects occur

Engineering Contradiction:

Improveweight loss efficacyVSAvoidside effects

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the molecular target parameter from conventional obesity drugs to Nrf2 activators, fundamentally altering the mechanism of action. This parameter change enables weight loss through antioxidant and anti-inflammatory pathways rather than traditional appetite suppression or metabolism manipulation, thereby achieving efficacy with minimal side effects.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces Nrf2 as an intermediary transcription factor that mediates the effects of antioxidant and anti-inflammatory compounds. By activating Nrf2, the drug achieves weight loss through indirect mechanisms involving oxidative stress reduction and inflammation modulation, avoiding direct adverse effects on multiple body systems.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If antioxidant inflammation modulators are used, then side effects are minimized, but weight loss efficacy must be demonstrated

Engineering Contradiction:

Improveside effectsVSAvoidweight loss efficacy

Core Design Contradiction:

Object-affected harmful factorsVSProductivity

Solution Approach 1:

The patent demonstrates that Nrf2 activators perform multiple functions simultaneously: they provide antioxidant protection, reduce inflammation, and induce weight loss. This multi-functionality allows a single mechanism to address obesity while avoiding the side effects associated with targeted single-function drugs, as the same pathway affects multiple physiological processes beneficially.

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Adaptability or versatility

If multiple medications are combined for obese patients, then comprehensive treatment is achieved, but drug interactions and safety issues increase

Engineering Contradiction:

Improvecomprehensive treatmentVSAvoiddrug safety

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent segments the treatment approach by identifying Nrf2 activation as a distinct therapeutic mechanism that can work independently or in combination with other treatments. By establishing Nrf2 activation as a modular approach, the patent enables safe combination with other medications (antidiabetic, antihypertensive, cholesterol-reducing agents) without significant interactions, as each drug acts through different primary mechanisms.

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS11911395B2Methods of treating obesity using antioxidant inflammation modulators

Publication Date: 2024.02.27 REATA PHARMACEUTICALS HOLDINGS LLC

AI summary

The present invention relates to methods of treating and/or preventing obesity comprising the administration of antioxidant inflammation modulators described herein, including for example bardoxolone methyl.